Immune System Biotech Odyssey Seeks $238.3 Million in US IPO
Odyssey Therapeutics Inc., a clinical stage biotechnology firm focused on autoimmune and inflammatory diseases, is seeking to raise $238.3 million in an initial public offering.
Original Source
Read the full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.